SMAD3 and non-small cell lung carcinoma: For example, miR-32-5p inhibits migration and invasion in non-small cell lung cancer (NSCLC) by targeting SMAD3 and modulating the TGF-β/SMAD signalling pathway, which is crucial for tumour progression and immune regulation [36].